S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
⚡ 2,467% Return on Israeli Laser Company? (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Biden and GOP reach debt-ceiling deal. Now Congress must approve it to prevent calamitous default
3 Free Stock Picks per Day (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Erdogan takes lead in unofficial count in Turkey’s presidential runoff
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
⚡ 2,467% Return on Israeli Laser Company? (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Biden and GOP reach debt-ceiling deal. Now Congress must approve it to prevent calamitous default
3 Free Stock Picks per Day (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Erdogan takes lead in unofficial count in Turkey’s presidential runoff
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
⚡ 2,467% Return on Israeli Laser Company? (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Biden and GOP reach debt-ceiling deal. Now Congress must approve it to prevent calamitous default
3 Free Stock Picks per Day (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Erdogan takes lead in unofficial count in Turkey’s presidential runoff
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
⚡ 2,467% Return on Israeli Laser Company? (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Biden and GOP reach debt-ceiling deal. Now Congress must approve it to prevent calamitous default
3 Free Stock Picks per Day (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Erdogan takes lead in unofficial count in Turkey’s presidential runoff
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
NASDAQ:COYA

Coya Therapeutics (COYA) Stock Forecast, Price & News

$4.37
+0.22 (+5.30%)
(As of 05/26/2023 ET)
Compare
Today's Range
$4.10
▼
$4.44
50-Day Range
$3.82
▼
$5.83
52-Week Range
$3.68
▼
$8.00
Volume
67,265 shs
Average Volume
299,991 shs
Market Capitalization
$43.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00
ProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Coya Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
105.9% Upside
$9.00 Price Target
Short Interest
Healthy
0.33% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.52mentions of Coya Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

Medical Sector

649th out of 1,012 stocks

Pharmaceutical Preparations Industry

325th out of 495 stocks

See Top Rated MarketRank™ Stocks Here

COYA stock logo

About Coya Therapeutics (NASDAQ:COYA) Stock

Coya Therapeutics Inc. is a clinical-stage biotechnology company. It involved in developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells to target systemic inflammation and neuroinflammation. The company's therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Coya Therapeutics Inc. is based in HOUSTON.

Receive COYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coya Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

COYA Stock News Headlines

May 23, 2023 | markets.businessinsider.com
Pre-market Movers: BIOC, MVLA, COYA, PACW, OMH…
May 22, 2023 | finance.yahoo.com
Coya to Present Additional Biomarker and Brain Imaging Data for COYA 301 in Alzheimer’s Disease (AD) at the LD Micro Conference on June 7, 2023
May 28, 2023 | Behind the Markets (Ad)
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
May 20, 2023 | americanbankingnews.com
Coya Therapeutics (NASDAQ:COYA) Now Covered by BTIG Research
May 18, 2023 | msn.com
BTIG Initiates Coverage of Coya Therapeutics (COYA) with Buy Recommendation
May 17, 2023 | msn.com
Chardan Capital Reiterates Coya Therapeutics (COYA) Buy Recommendation
May 16, 2023 | seekingalpha.com
Coya: Outstanding Data In ALS And Alzheimer's Justify Large Upside
May 16, 2023 | benzinga.com
Why Coya Therapeutics Shares Are Shooting Higher Today
May 28, 2023 | Behind the Markets (Ad)
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser
Small cap wins $1.65 billion contract to make them. GlobeNewswire says this is a $51.1 Billion market by 2026. See why this stock could soar 2,476% >>>
May 16, 2023 | msn.com
Coya surges ~25% after COYA 301 shows promise in Alzheimer’s study
May 16, 2023 | finance.yahoo.com
Here's Why Momentum in Coya Therapeutics, Inc. (COYA) Should Keep going
May 16, 2023 | finance.yahoo.com
Coya Therapeutics’ COYA 301 Increased Treg Function and Halted Cognitive Decline in an Open Label Study in Patients with Alzheimer’s Disease
May 12, 2023 | finance.yahoo.com
Is Coya Therapeutics (NASDAQ:COYA) In A Good Position To Invest In Growth?
May 12, 2023 | msn.com
EF Hutton Reiterates Coya Therapeutics (COYA) Buy Recommendation
May 11, 2023 | marketwatch.com
2023 Regulatory T Cell Tregs Therapies Market Size and Regional Analysis in Medical Care Sector | with [112 Pages] and Forecast till 2031
May 10, 2023 | investing.com
Leap Therapeutics Inc (LPTX)
May 10, 2023 | finance.yahoo.com
Coya Therapeutics, Inc. Provides Business Update and Reports Q1 2023 Unaudited Financial Results
May 8, 2023 | benzinga.com
Positive Financials Along With Promising Clinical Results – Coya Therapeutics
May 4, 2023 | msn.com
EF Hutton Initiates Coverage of Coya Therapeutics (COYA) with Buy Recommendation
April 23, 2023 | americanbankingnews.com
Coya Therapeutics (NASDAQ:COYA) Trading Up 8%
April 14, 2023 | finance.yahoo.com
Alzheimer’s Disease Largely Remains A Mystery, With A Lack Of Highly Effective Treatments - Could Regulatory T-Cells (Tregs) Be The Answer?
April 3, 2023 | americanbankingnews.com
Coya Therapeutics (NASDAQ:COYA) Receives Buy Rating from Chardan Capital
March 31, 2023 | finance.yahoo.com
Coya Therapeutics to Present Biomarker and Preliminary Efficacy Clinical Data for COYA 301 for the Treatment of Patients with Alzheimer’s Disease (AD) at the 2023 Keystone Symposia Meeting for Neurodegeneration held on May 15-19th, 2023
March 30, 2023 | markets.businessinsider.com
Coya Therapeutics, Inc. (COYA) Gets a Buy from Chardan Capital
March 29, 2023 | msn.com
Coya Therapeutics GAAP EPS of -$4.73 misses by $2.91
March 29, 2023 | finance.yahoo.com
Coya Therapeutics, Inc. Provides Business Update and Reports FY 2022 Unaudited Financial Results
March 28, 2023 | benzinga.com
There Is No Cure For ALS, But Coya Therapeutics Might Have The Answer According To A New Clinical Study
See More Headlines
Receive COYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coya Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

COYA Company Calendar

Today
5/28/2023
Next Earnings (Estimated)
8/09/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:COYA
CUSIP
N/A
CIK
1835022
Web
www.coyatherapeutics.com
Phone
800-587-8170
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+105.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
13.69
Quick Ratio
13.69

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.62 per share
Price / Book
2.70

Miscellaneous

Outstanding Shares
9,948,000
Free Float
N/A
Market Cap
$43.47 million
Optionable
Not Optionable
Beta
N/A














COYA Stock - Frequently Asked Questions

Should I buy or sell Coya Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Coya Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" COYA shares.
View COYA analyst ratings or view top-rated stocks.

What is Coya Therapeutics' stock price forecast for 2023?

2 equities research analysts have issued 12 month price targets for Coya Therapeutics' stock. Their COYA share price forecasts range from $9.00 to $9.00. On average, they anticipate the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 105.9% from the stock's current price.
View analysts price targets for COYA or view top-rated stocks among Wall Street analysts.

How have COYA shares performed in 2023?

Coya Therapeutics' stock was trading at $4.7381 on January 1st, 2023. Since then, COYA stock has decreased by 7.8% and is now trading at $4.37.
View the best growth stocks for 2023 here.

When is Coya Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our COYA earnings forecast.

When did Coya Therapeutics IPO?

(COYA) raised $15 million in an IPO on Thursday, December 29th 2022. The company issued 3,050,000 shares at a price of $5.00 per share.

What is Coya Therapeutics' stock symbol?

Coya Therapeutics trades on the NASDAQ under the ticker symbol "COYA."

When does the company's lock-up period expire?

Coya Therapeutics' lock-up period expires on Tuesday, June 27th. Coya Therapeutics had issued 3,050,000 shares in its public offering on December 29th. The total size of the offering was $15,250,000 based on an initial share price of $5.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.

Who are Coya Therapeutics' major shareholders?

Coya Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (0.08%).

How do I buy shares of Coya Therapeutics?

Shares of COYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Coya Therapeutics' stock price today?

One share of COYA stock can currently be purchased for approximately $4.37.

How much money does Coya Therapeutics make?

Coya Therapeutics (NASDAQ:COYA) has a market capitalization of $43.47 million.

How can I contact Coya Therapeutics?

The official website for the company is www.coyatherapeutics.com. The company can be reached via phone at 800-587-8170 or via email at ir@coyatherapeutics.com.

This page (NASDAQ:COYA) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -